Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From Precision to Personalized: Catalyzing AI-Enabled Innovation in Drug Development.

Clinical and translational science·2026

Same author

History and Evolution of Innovations in Clinical Pharmacology.

Clinical pharmacology and therapeutics·2025

Same author

A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy.

Pharmacotherapy·2025

Same author

Evaluating Tranexamic Acid Dosing Strategies for Postpartum Hemorrhage: A Population Pharmacokinetic Approach in Pregnant Individuals.

Journal of clinical pharmacology·2025

Same author

Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products.

CPT: pharmacometrics & systems pharmacology·2024

Same author

In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science.

Journal of pharmacokinetics and pharmacodynamics·2024

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Quantitative disease, drug, and trial models.

Jogarao V S Gobburu¹, Lawrence J Lesko

¹Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993-0002, USA. jogarao.gobburu@fda.hhs.gov

Annual Review of Pharmacology and Toxicology

|October 15, 2008

Summary

This summary is machine-generated.

Quantitative disease-drug-trial models enhance pharmaceutical R&D by leveraging prior data for future drug development. Collaborative efforts are crucial for building and sharing these valuable predictive models.

Related Experiment Videos

Last Updated: Jun 29, 2026

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Pharmacometrics
Quantitative Systems Pharmacology
Drug Development Science

Background:

Quantitative models are essential for learning from past pharmaceutical research and development.
Integrating disease, drug, and trial models can optimize future drug development planning.
Current models often lack integration and public accessibility, hindering broader application.

Purpose of the Study:

To propose working definitions and structures for quantitative disease-drug-trial models.
To outline strategies for applying these models in future development and regulatory decision-making.
To advocate for public sharing of disease and trial models to foster collaboration.

Main Methods:

Defining key components of disease, drug, and trial models.
Illustrating model applications with examples.
Discussing challenges and potential solutions for model development and implementation.

Main Results:

Disease and trial models are largely product-independent, facilitating broader application.
Drug models are specific to the compound, requiring tailored development.
A collaborative, multi-stakeholder approach is necessary for successful model creation.

Conclusions:

Developing robust disease-drug-trial models requires a concerted effort from industry, academia, and regulatory bodies.
Publicly sharing disease and trial models can accelerate pharmaceutical innovation.
These integrated models offer a powerful solution to improve R&D productivity and inform regulatory decisions.